The Biologics Manufacturing Centre (BMC) Inc. positions itself as a key player in biomanufacturing by offering end-to-end production services tailored to the needs of emerging biotech companies and established pharmaceutical firms. Its mission is to support partners in the production
Lonza has selected Hyderabad, India, as the site for a new Global Capability Centre (GCC), a move intended to support the company’s global biopharmaceutical operations and strengthen the city’s role in the life sciences sector. The Switzerland-headquartered company operates as
Lonza has entered into a definitive agreement to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion (USD 3 billion). The company will receive CHF 1.7 billion (USD 2.2
FREE WHITEPAPER 8 Critical Questions for CDMO Selection Avoiding common outsourcing pitfalls. Selecting the wrong CDMO doesn’t just slow your timeline — it can cost you nine months and your entire launch window. This guide gives you the questions that
Upperton has submitted an application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for approval of a 7,000 sq. ft sterile manufacturing facility in Nottingham, UK. The submission follows the completion of aseptic process simulation validation batches carried
Matrix Pharma Corp has inaugurated a new oncology manufacturing facility, Unit-8, in Vizag, India. The facility is designed to support the production of highly potent active pharmaceutical ingredients (HPAPIs) for oncology applications and strengthens the company’s manufacturing infrastructure for high-potency
Lifecore Biomedical has entered into a development services agreement with Indomo to support the development of DT-001, a corticosteroid drug candidate designed to treat inflammatory acne lesions. The collaboration expands the relationship between the two companies, with Lifecore providing contract
Frontage Laboratories has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd., a clinical research laboratory service provider based in China. The transaction is intended to expand Frontage’s laboratory service capabilities and strengthen its operational footprint in China and
Altruist Biologics has introduced Altru-CON™, a formulation technology platform designed to support the development and commercialisation of high-concentration biologics. The platform enables protein concentrations of up to 200 mg/mL while achieving more than a two-fold reduction in viscosity. The technology
Minaris has launched AgentSCREEN™, a next-generation sequencing (NGS) platform designed to detect adventitious viruses in biologics and advanced therapy products. The GMP-qualified testing platform aims to support viral safety testing for pharmaceutical and biotechnology companies developing monoclonal antibodies, vaccines, and
